ClinicalTrials.gg
CompletedNCT06941818Updated Oct 14, 2026

HS-IT101 Injection in the Treatment of Advanced Melanoma(FASTIL-Mela01)

A Phase 1 interventional study of HS-IT101 Injection in Advanced Melanoma, sponsored by Hangzhou Huasai Biomedicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Hangzhou Huasai Biomedicine Co., Ltd. · Phase 1, Interventional, and Treatment

Updated Oct 14, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 203 studies in Melanoma with a site in China — 83 open to participants now, 95 under way, 5 of them phase 3. Melanoma · China.

Enrollment
185th of 189
5 · median 50
Started
2025
with 22 others
Phase 1
57 of 203
19 open now
Registered
162nd of 203
by date

Among the 203 studies in Melanoma with a site in China, this one is the 185th largest by enrollment of the 189 interventional ones that give a count, is one of 23 that started in 2025, is one of 57 in phase 1, and was the 162nd registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.

Browse Melanoma studies →

Open to participants now

83 of the 203 studies in Melanoma with a site in China are open now. Recruiting first, the newest first:

78 more — sign in →

All 83 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 203 studies in Melanoma with a site in China, or all of them as a file.
02

Study summary

Single-arm, open-label,interventional study evaluating adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocyte (TIL) infusion (HS-IT101) after lymphodepletion preparative with fludarabine and cyclophosphamide regimen, followed by IL-2, for the treatment of patients with advanced melanoma.

Read the detailed description

HS-IT101 is an adoptive cell transfer therapy that utilizes an autologous TIL manufacturing process, for the treatment of patients with advanced melanoma. The cell transfer therapy used in this study involves patients receiving lymphodepletion treatment with fludarabine and cyclophosphamide, followed by infusion of autologous TIL, then finnaly followed by the administration of a regimen of IL-2.

03

Conditions studied

  • Advanced Melanoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 18 and 75 years (inclusive).
  2. or cytologically confirmed advanced, recurrent, or melanoma (excluding uveal melanoma) that has failed at least one prior line of standard systemic therapy. Subjects with BRAF V600 mutations must have failed BRAF-targeted therapy or been intolerant to such therapy due to toxicity. The necessity and appropriateness of targeted therapy shall be determined by the investigator based on the subject's clinical status.
  3. At least one tumor lesion (not subjected to radiotherapy or local therapy within 28 days prior to sampling) must be available for autologous tumor-infiltrating lymphocyte (TIL) preparation, with a minimum tissue weight of ≥0.050 g.
  4. At least one (per 1.1 criteria) must remain after sampling. This lesion must not have received prior radiotherapy or local therapy unless performed >28 days before tumor sampling and demonstrating clear progression.
  5. performance status ≤1.
  6. ≥3 months.
  7. Adequate organ and bone marrow function at screening, defined as:

    Hematology:

    (ANC) ≥1.5×10⁹/L; count (PLT) ≥90×10⁹/L; (HGB) ≥90 g/L (no transfusion or erythropoietin within 14 days).

    Liver function:

    /AST ≤2.5× (≤5×ULN for liver metastases); Total (TBil) ≤1.5×ULN (≤3×ULN if Gilbert's syndrome is confirmed).

    Renal function:

    Serum creatinine (Cr) ≤1.5×ULN or (Ccr) ≥60 mL/min (Cockcroft-Gault formula).

    Coagulation:

    (APTT) ≤1.5×ULN; International normalized ratio (INR) and prothrombin time (PT) ≤1.5×ULN.

  8. Cardiac function criteria:

    (LVEF) ≥50% by echocardiography; No arrhythmias requiring treatment; interval ≤470 ms (calculated using Fridericia's formula: QTcF = QT/(RR⁰.³³), where RR = 60/heart rate. If initial result is abnormal, repeat twice at 5-minute intervals; use mean value for eligibility); Baseline oxygen saturation >91% in room air.

  9. Prior treatment-related toxicities resolved to v5.0 Grade ≤1 (excluding alopecia or other toxicities deemed non-risk by the investigator) before tumor sampling.
  10. Agreement to use effective non-pharmacologic from signing until 1 year post-TIL infusion.
  11. Willing and able to comply with study visits/procedures, with full understanding of the trial and provision of written informed consent.

Exclusion criteria

Exclusion Criteria:

  1. History of severe allergic reactions to medications used in the study (including but not limited to cyclophosphamide, fludarabine, IL-2, gentamicin, amphotericin B, or components of TIL infusion).
  2. Uncontrolled clinical conditions, including:

    • Poorly controlled hypertension (resting systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg despite medication);
    • Congestive heart failure ( Class III/IV).
  3. Within 6 months prior to screening:

    Deep vein thrombosis, pulmonary embolism, myocardial infarction, severe/unstable arrhythmia, angina pectoris, percutaneous coronary intervention, acute coronary syndrome, coronary artery bypass graft, cerebrovascular accident, , or cerebral embolism.

  4. Active diseases requiring systemic therapy during the study period (except: eczema, vitiligo, psoriasis, alopecia, or Graves' disease not requiring systemic treatment in the past 2 years; hypothyroidism managed with thyroid hormone replacement; type 1 diabetes managed with insulin; or autoimmune conditions deemed non-recurrent by the investigator).
  5. History of organ transplantation or hematopoietic stem cell transplantation.
  6. Use of drugs (e.g., ) within 4 weeks prior to tumor sampling, or concurrent conditions requiring immunosuppressive therapy during the study. Exceptions:

    • Physiological-dose glucocorticoids (≤12 mg/m²/day hydrocortisone or equivalent);
    • Topical or intranasal steroids.
  7. Systemic anticancer therapy within 4 weeks prior to preconditioning (including drugs; applies to agents with a half-life \<4 weeks [whichever is shorter]) or plans to participate in other interventional trials during the study.
  8. Acute/chronic infections, including:

    • positivity, syphilis antibody positivity, or active /C (subjects with HBsAg/HBeAg positivity are eligible if HBV DNA is below the lower limit of detection [LLOD]; HCVAb-positive subjects are eligible if is below LLOD);
    • Active infections requiring systemic therapy or active tuberculosis.
  9. Major organ surgery, significant trauma within 4 weeks prior to screening, or planned elective surgery during the trial.
  10. Surgical complications or delayed wound healing (investigator-assessed to increase risks of preconditioning, TIL therapy, or IL-2 administration).
  11. Other primary diagnosed within 5 years prior to screening (exceptions: radically treated basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ).
  12. Severe respiratory diseases (e.g., interstitial lung disease, severe , pulmonary insufficiency, symptomatic bronchospasm).
  13. Gastrointestinal bleeding requiring surgery, intestinal ischemia, or perforation.
  14. or uncontrolled/untreated (excludes asymptomatic CNS metastases stable for ≥4 weeks post-treatment without corticosteroids/anticonvulsants).
  15. Prior treatment with cell therapy products of the same class.
  16. Pregnancy, lactation, or refusal to use .
  17. Psychiatric disorders, substance abuse, or other investigator-determined .
Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    HS-IT101 monotherapy

    TIL Injection administered by intravenous infusion over 30-60 minutes.

    Drug: HS-IT101 Injection

Interventions

  • Adoptive transfer of 5x10\^9-6x10\^10 autologous TIL to patients i.v. in 30-60 minutes.

06

What researchers measure

Primary outcomes

  1. Adverse Events (AE)

    To characterize the safety profile of HS-IT101 in patients with advanced solid tumor as assessed by incidence of adverse events

    Time frame: 12 months

  2. Serious Adverse Events (SAE)

    To characterize the safety profile of HS-IT101 in patients with advanced solid tumor as assessed by incidence of serious adverse events

    Time frame: 12 months

  3. Objective Response Rate (ORR)

    To evaluate the efficacy of HS-IT101 in patients with advanced solid tumor, based on the objective response rate (ORR) as assessed by the Independent Review Committee (IRC) per RECIST v1.1

    Time frame: Up to 36 months

  4. Time-to-response (TTR)

    To evaluate the efficacy of HS-IT101 in patients with advanced solid tumor by assessing the time-to-response (TTR) as assessed by the Investigator per RECIST v1.1

    Time frame: Up to 36 months

  5. Duration of Response (DOR)

    To evaluate the efficacy of HS-IT101 in patients with advanced solid tumor by assessing the duration of response (DOR) as assessed by the Investigator per RECIST v1.1

    Time frame: Up to 36 months

  6. Disease Control Rate (DCR)

    To evaluate the efficacy of HS-IT101 in patients with advanced solid tumor, based on the disease control rate (DCR) as assessed by the Independent Review Committee (IRC) per RECIST v1.1

    Time frame: Up to 36 months

  7. Progression-Free-Survival (PFS)

    To evaluate progression-free-survival (PFS) in patients with advanced solid tumor

    Time frame: Up to 36 months

  8. Overall Survival (OS)

    To evaluate overall survival (OS) in patients with advanced solid tumor

    Time frame: Up to 36 months

Secondary outcomes

  1. Pharmacokinetic (PK) detection parameters for HS-IT101

    Pharmacokinetic (PK) detection parameters for HS-IT101 injection include peripheral blood lymphocyte subsets and T-cell receptor (TCR) clonality.

    Time frame: Up to 6 months

07

Study locations

1 site
  • Peking University Cancer Hospital
    Beijing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Feb 2026, 7 months.

Of 226 industry-sponsored phase 1 interventional studies under Melanoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 66. This study's 7 months is below that.

Counting every sponsor, half of 412 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion May 2026 → Feb 2026 and completion May 2027 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2025
First posted
Apr 24, 2025
StartActual
Jul 10, 2025
Primary completionActual
Feb 20, 2026was May 2026
CompletionActual
Oct 1, 2026was May 2027
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Completed
changed Oct 14, 2026
Primary completion
May 30, 2026→Feb 20, 2026 (actual)
Oct 14, 2026
Study completion
May 30, 2027→Oct 1, 2026 (actual)
Oct 14, 2026
Enrollment
10 (estimated)→5 (actual)
Oct 14, 2026
Title
HS-IT101 Injection in the Treatment of Advanced Melanoma(FASTIL-Mela01)
Oct 14, 2026
Sponsor
Qingdao Sino-Cell Biomedicine Co., Ltd.→Hangzhou Huasai Biomedicine Co., Ltd.
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Enrolling by invitation→Completed
    Primary completion May 30, 2026→Feb 20, 2026 (now actual)
    Study completion May 30, 2027→Oct 1, 2026 (now actual)
    Enrollment 10 (estimated)→5 (actual)
    Sponsor Qingdao Sino-Cell Biomedicine Co., Ltd.→Hangzhou Huasai Biomedicine Co., Ltd.
    Title HS-IT101 Injection in the Treatment of Advanced Melanoma(FASTIL-Mela01)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06941818
Lead sponsor
Hangzhou Huasai Biomedicine Co., Ltd.
Responsible party
Sponsor
First posted
Apr 24, 2025
Start date
Jul 10, 2025
Primary completion
Feb 20, 2026
Completion
Oct 1, 2026
Last update
Oct 14, 2026

Study contacts

Jun Guo, MD
principal investigator · Peking University Cancer Hospital & Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Autologous Tumor-infiltrating Lymphocytes HS-IT101

Start the discussion